Paclitaxel protein-bound (Intravenous)
Medically reviewed by Drugs.com. Last updated on May 2, 2022.
Severe MyelosuppressionDo not administer paclitaxel protein-bound particles therapy to patients with baseline neutrophil counts less than 1500 cells/mm(3).Monitor for neutropenia, which may be severe and result in infection or sepsis.Perform frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles .
Commonly used brand name(s)
In the U.S.
- Abraxane
Available Dosage Forms:
- Powder for Suspension
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Mitotic Inhibitor
Uses for paclitaxel protein-bound
Paclitaxel protein-bound injection is used to treat metastatic breast cancer (cancer that has already spread) after other treatments have failed. It is used together with carboplatin, a cancer medicine, to treat advanced or metastatic non-small cell lung cancer in patients who cannot receive radiation therapy or have surgery. Paclitaxel protein-bound is used together with gemcitabine, a cancer medicine, to treat metastatic pancreas cancer.
Paclitaxel belongs to the group of medicines called antineoplastics (cancer medicines). It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by paclitaxel, other unwanted effects will also occur.
Paclitaxel protein-bound is to be given only by or under the direct supervision of a doctor.
Before using paclitaxel protein-bound
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For paclitaxel protein-bound, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to paclitaxel protein-bound or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of paclitaxel protein-bound injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of paclitaxel protein-bound injection in the elderly. However, elderly patients are more likely to have unwanted effects which may require caution in patients receiving paclitaxel protein-bound.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving paclitaxel protein-bound, it is especially important that your healthcare pr..
